Key terms
About XNCR
Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XNCR news
Today
11:16am ET
Xencor (XNCR) Receives a Buy from Bank of America Securities
Today
8:46am ET
Xencor (XNCR) Receives a New Rating from Wedbush
Today
8:26am ET
Buy Rating Affirmed for Xencor on Strategic Focus and Strong Financial Position
Today
8:17am ET
Buy Rating Affirmed for Xencor on Strong Pipeline and Financials: Anticipated IND Filing and T-cell Engager Developments
Today
8:04am ET
Piper Sandler Keeps Their Hold Rating on Xencor (XNCR)
Today
6:40am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Today
5:50am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sangamo Biosciences (SGMO), Xencor (XNCR) and Evolent Health (EVH)
Apr 16
7:12am ET
Xencor price target lowered to $38 from $56 at BTIG
Apr 09
8:32am ET
Xencor Inc Announces CFO Transition and Executive Compensation Plan
Mar 01
1:01am ET
Bad News for Xencor Inc. Stock: This New Risk Has Been Added
Mar 01
1:01am ET
Xencor’s Strategic Focus and Pipeline Progress Affirm Buy Rating
Feb 28
12:40pm ET
Xencor downgraded to Neutral at Piper after death of patient using vudalimab
Feb 28
12:33pm ET
Xencor downgraded to Neutral from Overweight at Piper Sandler
Feb 28
8:54am ET
Xencor price target lowered to $34 from $38 at BMO Capital
Feb 28
8:47am ET
Xencor price target lowered to $34 from $36 at Wedbush
Feb 28
7:19am ET
Xencor price target raised to $38 from $36 at Canaccord
Feb 28
7:16am ET
Xencor (XNCR) Receives a Buy from RBC Capital
Feb 28
7:02am ET
Analysts Are Bullish on Top Healthcare Stocks: Alcon (ALC), Xencor (XNCR)
Feb 28
6:20am ET
Analysts Offer Insights on Healthcare Companies: Xencor (XNCR) and Vaxcyte (PCVX)
Feb 28
3:36am ET
Barclays Sticks to Their Sell Rating for Xencor (XNCR)
Feb 27
9:35pm ET
Xencor (XNCR) Gets a Buy from TD Cowen
Feb 27
4:08pm ET
Xencor expects cash to fund operations into 2027
Feb 27
4:06pm ET
Xencor reports Q4 EPS (31c), consensus (9c)
No recent press releases are available for XNCR
XNCR Financials
Key terms
Ad Feedback
XNCR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XNCR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
